New Register-based Data on Use of Interferon Beta, Including Rebif®, in Women with Multiple Sclerosis Show No Effect on Pregnancy Outcomes
Merck, a leading science and technology company, today announced that new data on pregnancy outcomes at birth after exposure to interferon beta (IFN β), including Rebif® (sc/subcutaneous interferon beta-1a), will be presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Results showed no evidence that IFN β-exposure before and during pregnancy in women with multiple sclerosis (MS) affected infant birth weight for gestational age and head circumference. The results are based on data from Finnish and Swedish health registers collected between 1996-2014.
“Our priority is ensuring we address the needs of people living with MS,” said Dr. Maria Rivas, Chief Medical Officer at Merck. “When a woman is diagnosed with MS she may have questions on continuing treatment during pregnancy and how it could affect her unborn child. We are proud to collaborate with academia and health authorities to provide relevant safety information to physicians and patients.”
Among 666 IFN β-exposed and 1,330 unexposed live births, the prevalence of pregnancy outcomes were similar and not statistically different between the IFN β-exposed versus the unexposed patients. The prevalence of small for gestational age in the exposed cohort was 2.1% (95% CI 1.2-3.5) versus 2.0% (95% CI 1.3-2.9) for the unexposed, and large for gestational age was 0.8% (95% CI 0.2-1.7) for the exposed versus 0.8% (95% CI 0.4-1.5) for the unexposed. The prevalence of low birth weight was 3.9% (95% CI 2.6-5.7) among IFN β-exposed and 4.8% (95% CI 3.7-6.1) among the unexposed. Among 619 IFN β-exposed and 1,219 unexposed full-term births, the prevalence of low head circumference was 1.9% (95% CI 1.0-3.4) among the IFN β-exposed versus 1.1% (95% CI 0.6-1.8) among the unexposed.
These data points expand on safety data presented at recent congresses, which suggest exposure to IFN β does not increase risk of spontaneous abortions or affect other pregnancy outcomes, such as ectopic pregnancies or fetal malformations.
“Most women are diagnosed with MS at a time in their lives when they may be thinking about starting or extending a family, making their treatment decision more complex,” said Professor Kerstin Hellwig, Department of Neurology at St. Josef Hospital, Germany. “These data add to our wealth of knowledge to better understand the safety of interferon beta treatment during pregnancy.”
In the EU, the initiation of Rebif during pregnancy is currently contraindicated by the European Medicines Agency (EMA), see section 4.3 and 4.6 in the EU Summary of Product Characteristics (SMPC) for Rebif. Merck has submitted regulatory filings with different health authorities to include safety data from these interferon registries in the Rebif label, and these reviews are currently ongoing.
Rebif® (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta protein produced by the human body. The efficacy of Rebif® in chronic progressive MS has not been established. Interferon ß is thought to help reduce inflammation. The exact mechanism is unknown.
Rebif®, which was approved in Europe in 1998 and in the US in 2002, is registered in more than 90 countries worldwide. Rebif® has been proven to delay the progression of disability, reduce the frequency of relapses and reduce MRI lesion activity and area.
Rebif® can be administrated with the RebiSmart® electronic auto-injection device (not approved in the US), or with the RebiDose® single-use disposable pen, or the manual multidose injection pen RebiSlide™. Rebif® can also be administered with the autoinjector Rebiject II® or by manual injection using ready-to-use pre-filled syringes. These injection devices are not approved in all countries.
In January 2012, the European commission approved the extension of the indication of Rebif® in early multiple sclerosis. The extension of the indication of Rebif® has not been submitted in the United States. Rebif® should be used with caution in patients with a history of depression, liver disease, thyroid abnormalities and seizures. Most commonly reported side effects are flu-like symptoms, injection site disorders, elevation of liver enzymes and blood cell abnormalities. Patients, especially those with depression, seizure disorders, or liver problems, should discuss treatment with Rebif® with their doctors.
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.3 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS, with a robust pipeline focusing on discovering new therapies that have the potential to modulate key pathogenic mechanisms in MS. Merck aims to improve the lives of those living with MS, by addressing areas of unmet medical needs.
The company`s robust immunology pipeline focuses on discovering new therapies that have the potential to modulate key pathogenic mechanisms in chronic diseases such as MS, systemic lupus erythematosus (SLE) and forms of arthritis, including rheumatoid arthritis (RA) and osteoarthritis (OA).
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck generated sales of € 14.8 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.
1 MS International Foundation. Who Gets MS? https://www.msif.org/about-ms/epidemiology-of-ms/. Accessed 14 August 2019
2 MS International Foundation. What is MS? https://www.msif.org/about-ms/what-is-ms/. Accessed 14 August 2019.
Tone Brauti Fritzen
+49 151 1454 2694
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Metanoia Announces Its Next Generation Broadband Access Technology14.10.2019 07:11:00 CEST | Press release
BROADBAND WORLD FORUM 2019--In order to respond to the ever increasing demand for higher data rate of xDSL over copper, coax lines, Metanoia Communications (“Metanoia”) announced today the launch of its latest family of chipsets that supports all the ITU-T Gfast (212MHz profile) and VDSL2 (35MHz profile) standards and builds on Metanoia’s proven Gfast, VDSL2 and ADSL2/2+ technology. With its MT-x2331 product family, Metanoia will deliver the industry first next generation broadband access xDSL PHY chipset for multiple applications including home gateways, low density xDSL Central Office systems and standalone xDSL termination, such as SFP modules. Emerging trends in the Broadband Access Networks make the use of standalone xDSL PHY solution more pertinent for WAN PHY agnostic platforms. A standalone xDSL PHY enables cost-effective upgrade of existing WAN deployments, an approach which is increasingly attractive to Operators. Metanoia MT-x2331 series is a chipset family that supports all
BIZCENTER USA Launches Coworking Facility in Orlando With Plans for Nationwide Franchise14.10.2019 04:01:00 CEST | Press release
Multimedia, Inc. (www.multimediausa.com) starts today the operations of BIZCENTER USA LLC, its affiliate for shared workspaces and virtual offices. Located on a fully owned 4,400 sq. ft. area in one of the most strategic regions of Orlando, Florida, BIZCENTER USA is offering brand-new state of the art executive suites in a facility with upscale conference rooms, reception, luxury lounge, and kitchen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191013005018/en/ Founded in Orlando in 1991, Multimedia is a leading marketing and communications company, highly recognized worldwide for its professional integrity, serving advertising agencies, direct clients and media outlets across all continents. According to Fernando Mariano, president of both companies, the creation of BIZCENTER USA fulfills the needs for a stylish shared workspace and virtual office facility in Southwest Orlando. “Multimedia has strong ties with the Orlando
Vodafone Idea and Mavenir Partner to Extend Network as a Platform14.10.2019 01:00:00 CEST | Press release
Mavenir, the industry's only end-to-end cloud-native 4G and 5G network software provider for CSPs today announced the extension of its partnership with Vodafone Idea Limited (VIL), India’s leading telecom operator, to extend VIL Network as a Platform, reaching distributed presence across all the major Industrial, Commercial, and Services clusters in India. This partnership will focus on three thrust areas. First, building a universal secured Cloud capable of hosting multiple tenants and third-party applications. Second, building a fully automated platform that enables self-provisioning of various workloads. Third and most importantly, setting up a joint innovation lab and team that will consistently innovate on Chipset, Operating System, and work at Application level to offer unique APIs and enable new use cases and delightful experience to VIL customers. “Vodafone Idea has the largest Edge Cloud deployment in India. Our partnership with Mavenir will enable continued innovation in opti
SHINE Creates Therapeutics Division, Will Attend 2019 European Association of Nuclear Medicine Conference12.10.2019 04:00:00 CEST | Press release
SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise. The company’s Therapeutics division will initially focus on the development and commercialization of lutetium‑177, or Lu‑177, a therapeutic isotope that is combined with a disease-specific targeting molecule to treat cancer. Targeting molecules deliver Lu‑177 atoms to cancer sites throughout the body, where they directly irradiate cancer cells. The first Lu‑177-based targeted radiotherapy (for neuroendocrine tumors) reached the market in 2018. Many high-potential targeted molecules for the treatment of a range of other cancers with Lu-177 are currently under investigation. SHINE is also evaluating additional medical isotopes with therapeutic properti
Smart Taxation – A Step Towards a Fair, Efficient and Growth-Friendly European Taxation Approach11.10.2019 22:01:00 CEST | Press release
In a rapidly changing global economy, smart taxation is essential to drive growth and economic prosperity. However, the European Union (EU) continues to fall behind as it persists with a one-size-fits all taxation system. This year’s GLOBSEC Tatra Summit hosts a Focus Group, bringing together international experts, looking to reshape and support a smarter European tax policy. Europe is at a crossroads in adapting its tax policy to the realities of today’s global economy. The EU plays a key role in overseeing national tax rules in some areas - particularly in relation to EU business and consumer policies. The institutional changeover marks a perfect opportunity for the Tatra Summit to place major topics on the radar of decision-makers and offer efficient recommendations. So now is the time to adapt the EU’s taxation model to be fit-for-purpose. With member states around the table, European fiscal authorities should design a model that does not have a disruptive impact on national needs
Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund11.10.2019 13:19:00 CEST | Press release
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement. "Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting,” said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer. “It is vital that the exp